Matthew Buss
Family Medicine · Merriam, KSNPI 1902998594
Payments from drug & device makers
Across 336 payments — averaging $13.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$974
- Novo Nordisk$640
- Lilly USA, LLC$404
- Pfizer$358
- AstraZeneca$307
- Amgen$257
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,614100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 72 | $974 |
| Novo Nordisk | 43 | $640 |
| Lilly USA, LLC | 27 | $404 |
| Pfizer | 38 | $358 |
| AstraZeneca | 19 | $307 |
| Amgen | 17 | $257 |
| GSK | 19 | $224 |
| Boehringer Ingelheim | 12 | $177 |
| Bayer | 9 | $148 |
| Johnson & Johnson | 13 | $148 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $122 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $117 |
| Amarin Pharma, Inc. | 6 | $93 |
| Sanofi Pasteur Inc. | 6 | $91 |
| Abbott | 5 | $88 |
| Antares Pharma, Inc. | 5 | $85 |
| Merck | 5 | $70 |
| Astellas Pharma US Inc | 5 | $59 |
| Daiichi Sankyo Inc. | 3 | $52 |
| Hologic Sales And Service, LLC | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Viiv Healthcare Company | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Organogenesis Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Radius Health, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
| Cranial Technologies, Inc | 1 | $12 |
How this compares
$4,625 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 116 | $116,567 |
| OzempicSemaglutide | 81 | $105,796 |
| XareltoRivaroxaban | 26 | $29,650 |
| EliquisApixaban | 30 | $29,624 |
| JanuviaSitagliptin Phosphate | 31 | $26,082 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $7,642 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $5,670 |
| GlyxambiEmpagliflozin/Linagliptin | 12 | $5,647 |
| Atorvastatin Calcium | 509 | $4,098 |
| Rosuvastatin Calcium | 229 | $3,070 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $2,824 |
| Ezetimibe | 104 | $2,796 |
| Pantoprazole Sodium | 163 | $2,547 |
| Duloxetine Hcl | 126 | $2,507 |
| Levothyroxine Sodium | 273 | $2,427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi | $177 | $122,214128 claims |
| Novo NordiskOzempic | $640 | $105,79681 claims |
| Johnson & JohnsonXarelto | $148 | $29,65026 claims |
| PfizerEliquis | $358 | $29,62430 claims |
| MerckJanuvia | $70 | $26,08231 claims |
| AbbVieSynthroid | $974 | $1,50220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Merriam
- Nicholas GatzMerriam$13K
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.